Introduction: Carbapenems have an important place in our antibiotic armamentarium and
have been trusted to effectively treat infections caused by ESBL-producing …

Background Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) are a
frequent cause of invasive infections worldwide. Carbapenems are nowadays the most used …

Several antimicrobial agents are being investigated as alternatives to carbapenems in the
treatment of infections caused by ESBL-producing Enterobacteriaceae, which may be useful …

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)–
producing pathogens is recognized globally as one of the most pressing concerns facing the …

The spread of multidrug-resistant Enterobacteriaceae is complicating the treatment of
nosocomial infections. In many parts of the world, resistance to third-generation …

Objectives To study the comparative mortality associated with carbapenems and alternative
antibiotics for the treatment of patients with extended-spectrum β-lactamase (ESBL)-positive …

Introduction: Extended spectrum β-lactamases (ESBL) and AmpC β-lactamases are
increasing causes of resistance in many Gram-negative pathogens of common infections …

Introduction: The spread of extended-spectrum β–lactamase (ESBL)-producing
Enterobacteriaceae has become a major public health threat worldwide. Area covered: A …

In this study, the activity of 18 non-carbapenem antibiotics was evaluated against 100
extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) and 50 ESBL …

Since 2006, extended-spectrum beta-lactamase (ESBL)-producing isolates have spread in
France, as well as elsewhere [1–3]. As these isolates are often multidrug-resistant …